Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan ...

WASHINGTON -- Patients with IgG4-related disease appeared to benefit from inebilizumab (Uplizna), currently approved for ...

Amgen (NASDAQ:AMGN) today announced the presentation of new data across its rare disease portfolio and pipeline at the annual ...

Amgen (AMGN) announced the presentation of new data across its rare disease portfolio and pipeline at the annual American College of ...

Zenas BioPharma, Inc. (ZBIO – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst ...

Our rare disease portfolio delivered $1.2 billion of sales in the quarter, growing 21% year-over-year, driven by TEPEZZA, KRYSTEXXA, UPLIZNA and TAVNEOS. These medicines are highly innovative ...

A council plans on battling “the plague” of shopping trolleys dumped in its rivers and streets by hitting supermarkets harder in the pocket. A wildlife reserve visitor centre has been damaged ...

A screenshot of the ABC News-hosted presidential debate between Kamala Harris and Donald Trump in September 2024. Picture: Youtube screenshot of Wall Street Journal debate stream Half of the world ...

THOUSAND OAKS, Calif. - Amgen (NASDAQ:AMGN) has revealed positive results from its Phase 3 MINT trial for UPLIZNA (inebilizumab-cdon), a treatment for adults with generalized myasthenia gravis (gMG).

THOUSAND OAKS, Calif. - Amgen (NASDAQ:AMGN) has revealed positive results from its Phase 3 MINT trial for UPLIZNA (inebilizumab-cdon), a treatment for adults with generalized myasthenia gravis (gMG).

Amgen said it achieved positive results from a Phase 3 trial of its treatment for adults with generalized myasthenia gravis, a rare autoimmune disorder. The biopharmaceutical company said Uplizna ...